Alexandra Gerlach, Content Producer

Clinical pharmacists can optimize treatment through effective medication management and therapeutic drug monitoring.

Pembrolizumab is a humanized monoclonal antibody that targets PD-1.

Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.

The test results are available in as little as 20 minutes.

In a study of 5 different drugs, amlodipine was the only one to reduce hyperactivity in patients with attention-deficit hyperactivity disorder (ADHD).

The approach targets cancer glucose and fatty acid metabolism, which is essential for cancer cell growth.

Treatment with semaglutide yielded superior effects on drinking outcomes compared with existing therapies to reduce alcohol cravings.

PfSPZ-LARC2 is a genetically engineered malaria vaccine that marks a significant step forward in combating malaria around the world.

The test offers an accurate, fast, low-cost, and noninvasive tool for early diagnosis of pancreatic ductal adenocarcinoma.

Pharmacists play a vital role in supporting patients with endometriosis through guidance on treatment options and managing side effects.

Research suggests H5N1 may be spreading undetected among humans, particularly in veterinarians with frequent animal exposure.

Nivolumab demonstrated a sustained disease-free survival benefit over placebo in high-risk muscle-invasive urothelial carcinoma (MIUC).

The approval makes the vaccine the first of its kind for this indication in the United States.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.

Pharmacists can support patients with treatment education, monitoring, and adherence, helping to overcome challenges posed by cognitive decline.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Avacincaptad pegol intravitreal solution is a prescription eye injection used to treat geographic atrophy.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

Vietnam war trauma continues to affect veterans’ health 50 years later.

The therapeutic vaccine could provide patients with a non-surgical alternative to traditional treatment approaches.